The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S2303: Randomized phase II/III trial of 2nd line nivolumab + paclitaxel + ramucirumab versus paclitaxel + ramucirumab in patients with PD-L1 CPS ≥ 1 advanced gastric and esophageal adenocarcinoma (PARAMUNE).
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Sarah Colby
No Relationships to Disclose
 
Paul Eliezer Oberstein
Consulting or Advisory Role - Amal Therapeutics; Aravive; AstraZeneca; AstraZeneca; Merck; QED Therapeutics; Rubius Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Amal Therapeutics (Inst); Arcus Biosciences (Inst); Merck (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst); Zai Lab (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Dan G. Duda
No Relationships to Disclose
 
Rajiv Agarwal
No Relationships to Disclose
 
Colmar Figueroa-Moseley
No Relationships to Disclose
 
Riha Vaidya
No Relationships to Disclose
 
Joseph M. Unger
Consulting or Advisory Role - AstraZeneca
 
Katherine A. Guthrie
No Relationships to Disclose
 
Flavio G Rocha
Consulting or Advisory Role - AstraZeneca; Histosonics; Medtronic; Oncosil
Travel, Accommodations, Expenses - Lynx Group
 
Maheswari Senthil
No Relationships to Disclose
 
Rachael A Safyan
Honoraria - Curio Science; Guardant Health
Research Funding - Merck (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Syma Iqbal
Honoraria - BeiGene
Consulting or Advisory Role - AstraZeneca; BMS; BMS; Daiichi Sankyo/Astra Zeneca; Merck
 
E. Gabriela Chiorean
Consulting or Advisory Role - Astellas Pharma; Axiom Healthcare Strategies; Bayer; Bristol-Myers Squibb/Celgene; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; IgM Biosciences; Ipsen; Merck; Merus; Novartis; Pfizer; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Erasca, Inc; FibroGen (Inst); Gilead/Forty Seven; Lonza (Inst); Merck (Inst); Novartis; Rafael Pharmaceuticals (Inst); Roche (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - G1 Therapeutics
 
Philip A. Philip
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Celgene; Daiichi Sankyo/Astra Zeneca; Guardant Health; Guardant Health; incyte; Ipsen; Merck; Rafael Pharmaceuticals; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bristol-Myers Squibb/Medarex; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals